Q.01

What counts as food for special medical purposes in Europe?

In the EU, a food counts as a food for special medical purposes (FSMP) if it meets the definition in Article 2(2)(g) of Regulation (EU) No 609/2013. It must be specially processed or formulated for the dietary management of patients, including infants, and used under medical supervision. It must also be for patients whose nutritional needs cannot be met "by modification of the normal diet alone" [1]. Commission Delegated Regulation (EU) 2016/128 then sorts FSMPs into three categories and sets the composition and labelling rules a product must meet before it can be sold.

Approach: I read the current consolidated Regulation (EU) No 609/2013 (version dated 1 September 2025) and its recitals. Delegated Regulation 2016/128 is not in the datasets, so I read it on EUR-Lex.

The legal test (Regulation 609/2013, Article 2(2)(g))

A product must meet all of these conditions [1]:

  1. Nature: it is food "specially processed or formulated". Normal foods are not FSMPs.
  2. Purpose: it is for the "dietary management of patients, including infants".
  3. Setting: it is "to be used under medical supervision".
  4. Use: it is for "the exclusive or partial feeding of patients". This covers products that are the only source of nutrition and products that are only part of the diet.
  5. Target population: patients who either:
    • have a "limited, impaired or disturbed capacity to take, digest, absorb, metabolise or excrete ordinary food or certain nutrients contained therein, or metabolites", or
    • have "other medically-determined nutrient requirements".
  6. Necessity: the patient's dietary management "cannot be achieved by modification of the normal diet alone".

The recitals add context:

  • FSMP is one of a few food categories that are "vital for the management of certain conditions" for clearly identified vulnerable groups [2].
  • A label may say what disease or condition the product is for. That is not treated as claiming the food prevents, treats or cures a disease [3].
  • Article 9(5) still bans claims that the product prevents, treats or cures a disease [4].
  • For low birth weight and pre-term infants, whether an infant FSMP is needed "is to be decided on a case-by-case basis" [5].

All FSMPs must also meet the general rules in Article 9: the composition must suit the intended users "in accordance with generally accepted scientific data", and no substance may be present at a level that endangers their health [4]. Where it is unclear whether a product is an FSMP, Article 3 allows the Commission to decide by implementing act whether a food falls under the Regulation and which category it belongs to [6].

The three categories (Delegated Regulation (EU) 2016/128, Article 2)

  • (a) Nutritionally complete, standard formulation: may be the only source of nutrition when used as the manufacturer instructs.
  • (b) Nutritionally complete, adapted for a specific disease, disorder or condition: may also be the only source of nutrition.
  • (c) Nutritionally incomplete, with either a standard or a disease-adapted formulation: not suitable as the only source of nutrition.

Categories (a) and (b) "may also be used as a partial replacement or as a supplement to the patient's diet". In every category the formulation "shall be based on sound medical and nutritional principles", and its use "shall be safe, beneficial and effective" in meeting the users' specific nutritional needs, "as demonstrated by generally accepted scientific data". Article 1 says an FSMP "may only be placed on the market if it complies with this Regulation".

What a compliant FSMP must also carry

Under Articles 5 to 9 of Delegated Regulation 2016/128 (EUR-Lex):

  • Extra mandatory label statements, on top of the general food labelling rules (Regulation 1169/2011):
    • that the product "must be used under medical supervision";
    • whether it is suitable as the only source of nutrition;
    • "For the dietary management of …", naming the condition;
    • a description of the properties that make it useful for that condition.
  • Nutrition declaration: expanded, and mandatory whatever the pack size. Values may not be shown as a percentage of reference intakes.
  • Claims: "Nutrition and health claims shall not be made" (Article 7).
  • Infant FSMPs must also meet these restrictions:
    • no pictures of infants;
    • packaging clearly different from infant formula;
    • advertising restricted to baby-care and scientific publications;
    • no point-of-sale promotion or samples.
  • Notification: the business must notify the national competent authorities with a model of the label, unless the Member State has another efficient monitoring system.

According to EUR-Lex, the Delegated Regulation applies from 22 February 2019, and from 22 February 2020 for infant FSMPs. It has been amended, and the latest consolidated version is dated 15 July 2021 (EUR-Lex). The article wording quoted above is from the text as adopted in 2016.

Q.02

What labelling and notification rules apply?

EU FSMP labelling and notification work in layers. Regulation (EU) No 609/2013 sets the general information rules and empowers the Commission to set detailed labelling and notification requirements. Delegated Regulation (EU) 2016/128 then sets those requirements. It requires an extra set of mandatory label statements, an expanded nutrition declaration on every pack, a ban on nutrition and health claims, tighter rules for infant FSMPs, and a model of the label sent to the competent authority of each Member State where the product is sold.

Approach: I read the in-force consolidated texts of Regulations 609/2013, 1169/2011 (food information) and 1924/2006 (claims). Delegated Regulation 2016/128 is not in the datasets, so I read its 2016 text as published in the Official Journal on EUR-Lex. I could not open its consolidated version or amendment history, so I can't confirm here whether later amendments changed Articles 4 to 9.

Framework rules (Regulation 609/2013)

  • Article 9(5): labelling, presentation and advertising "shall provide information for the appropriate use of such food". They "shall not mislead, or attribute to such food the property of preventing, treating or curing a human disease, or imply such properties" [4].
  • Article 9(6): this does not prevent sharing useful information or recommendations "exclusively intended for" people qualified in medicine, nutrition or pharmacy, or for other healthcare professionals in maternal care and childcare [4].
  • Article 11(1): empowers the Commission to adopt delegated acts on:
    • labelling, presentation and advertising, including authorising claims (point (c));
    • notification requirements "in order to facilitate the efficient official monitoring of such food". On that basis, food business operators "shall notify the competent authorities of Member States where that food is being marketed" (point (d));
    • specific rules for infant FSMPs (point (g)) [7].

Detailed rules (Delegated Regulation (EU) 2016/128, as adopted)

Baseline (Article 5(1)): "Unless otherwise provided in this Regulation", FSMPs "shall comply with Regulation (EU) No 1169/2011".

Name (Article 4, Annex IV): the legal name is fixed in each language. In English it is "Food for special medical purposes".

Additional mandatory particulars (Article 5(2)), on top of those in Article 9(1) of Regulation 1169/2011:

  • (a) a statement that the product must be used under medical supervision;
  • (b) whether it is suitable as the sole source of nourishment;
  • (c) that it is intended for a specific age group, as appropriate;
  • (d) where appropriate, that it poses a health hazard if consumed by people who do not have the target condition;
  • (e) "For the dietary management of …", naming the disease, disorder or condition;
  • (f) where appropriate, precautions and contra-indications;
  • (g) a description of the properties or characteristics that make the product useful for that condition, such as special processing and formulation, nutrients increased, reduced, eliminated or otherwise modified, and the rationale for use;
  • (h) where appropriate, a warning that it is not for parenteral use;
  • (i) instructions for preparation, use and storage after opening, as appropriate.

Items (a) to (d) "shall be preceded by the words 'important notice' or their equivalent". The legibility rules in Article 13(2) and (3) of Regulation 1169/2011 also apply to these particulars (Article 5(3)). Recital 14 says this product information is not a nutrition or health claim under Regulation 1924/2006.

Nutrition declaration (Article 6):

  • It must also include:
    • every Annex I vitamin and mineral present;
    • protein, carbohydrate and fat components, and other nutrients needed for appropriate use;
    • osmolality or osmolarity where appropriate;
    • the source and nature of the protein or protein hydrolysates.
  • It is mandatory "irrespective of the size of the largest surface of the packaging or container". Recital 15 says the small-pack exemption in point 18 of Annex V to Regulation 1169/2011 does not apply.
  • Values are for the food as sold and, where appropriate, as prepared. They "shall not be expressed as a percentage of the reference intakes".
  • It "shall not be repeated on the labelling" (a derogation from Article 30(3) of Regulation 1169/2011).
  • Nutrients not listed in Annex XV of Regulation 1169/2011 go after the most relevant Annex XV entry, or after the last one. Sodium sits with the minerals and may be repeated as "Salt: X g (of which sodium: Y mg)".

Claims (Article 7): "Nutrition and health claims shall not be made on food for special medical purposes."

Infant FSMPs (Article 8):

  • Mandatory particulars must be in a language consumers easily understand.
  • No pictures of infants, or other pictures or text that may idealise use. Graphics for identifying the product and showing preparation are permitted.
  • Text, images and colours must clearly distinguish the product from infant formula and follow-on formula.
  • Advertising is restricted to baby-care and scientific publications, and "shall contain only information of a scientific and factual nature". Member States "may further restrict or prohibit" it. Information intended only for healthcare professionals is not affected.
  • No point-of-sale advertising, samples or other retail promotion (displays, coupons, premiums, special sales, loss-leaders, tie-in sales).
  • Manufacturers and distributors may not give the public, pregnant women, mothers or their families free or low-priced products, samples or gifts.

Notification (Article 9):

  • When an FSMP is placed on the market, the food business operator "shall notify the competent authority of each Member State where the product concerned is being marketed".
  • It does so by sending "a model of the label used for the product", plus any other information the authority "may reasonably request to establish compliance".
  • A Member State may exempt operators "under a national system that guarantees an efficient official monitoring of the product concerned".
  • So notification happens country by country, not once at EU level.

Dates (Article 11): the rules apply from 22 February 2019, and from 22 February 2020 for infant FSMPs. Article 10 repeals Directive 1999/21/EC from 22 February 2019; it continued to apply to infant FSMPs until 21 February 2020.

How the general food-information regime fits

  • Article 7(3) of Regulation 1169/2011 bans disease-prevention, treatment or cure claims "subject to derogations provided for by Union law applicable to natural mineral waters and foods for particular nutritional uses" [8].
  • For FSMPs, Article 9(5) of Regulation 609/2013 bans those properties outright [4].
  • Naming the condition ("For the dietary management of …") is a required particular, not a disease claim. The recitals of Regulation 609/2013 say the same, as noted in the previous answer [3].

Each Member State's competent authority, and any national exemption from notification, is set nationally and is not in the sources I read. If you name your target markets, I can look up their notification routes.

Q.03

How does this differ from medical foods in America?

A US medical food covers much the same ground as an EU food for special medical purposes (FSMP), but the two are regulated in almost opposite ways. The EU sets a full regime of its own: three categories, composition rules, a long list of extra label statements, a nutrition declaration on every pack, a ban on nutrition and health claims, and notification to each Member State. In the US, a medical food is a statutory definition that mainly works as an exemption. It must follow general food rules, but it is exempt from Nutrition Facts labelling and from the nutrient content and health claim regulations. I found no premarket notification step for medical foods; the only filing FDA lists is food facility registration.

Approach: I read the current eCFR Title 21 food rules (Parts 101 and 107) and the FDA food guidance catalogue, then opened FDA's Frequently Asked Questions About Medical Foods, Third Edition (March 2023) on fda.gov. For the EU side I relied on Regulation 609/2013 and Delegated Regulation 2016/128 as covered in the previous answers.

Definition

US. The legal definition is in section 5(b) of the Orphan Drug Act (21 U.S.C. 360ee(b)(3)). A medical food is "formulated to be consumed or administered enterally under the supervision of a physician" and is "intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation" [9].

21 CFR 101.9(j)(8) adds five conditions. A product counts only if it:

  • (i) is "a specially formulated and processed product (as opposed to a naturally occurring foodstuff used in its natural state)", taken by mouth or by tube [10];
  • (ii) is for patients with limited or impaired capacity to ingest, digest, absorb or metabolise ordinary foods, or with other special medically determined needs, whose management "cannot be achieved by the modification of the normal diet alone" [11];
  • (iii) provides support modified for the needs of the specific disease, "as determined by medical evaluation" [12];
  • (iv) is intended for use under medical supervision [13];
  • (v) is only for a patient "receiving active and ongoing medical supervision", meaning recurring medical care that includes instructions on using the product [14].

EU. The core test is close to the US one, including the same phrase "cannot be achieved by modification of the normal diet alone" [1]. The differences are:

  • the EU requires "medical supervision", while the US statute says "supervision of a physician";
  • the EU definition expressly includes infants;
  • the US definition requires "distinctive nutritional requirements", and FDA adds the "active and ongoing" supervision condition.

FDA's narrow reading. In its FAQ guidance (FDA, 2023), FDA says it reads the definition "to narrowly constrain" the category. Medical foods are "not those simply recommended by a physician as part of an overall diet". On that basis, FDA:

  • says there are no distinctive nutritional requirements for diabetes and does not consider it a condition a medical food could be labelled for;
  • "generally would not consider" a product marketed for pregnancy, or for nutrient-deficiency diseases such as scurvy or pellagra, to qualify;
  • treats naturally low-protein conventional foods as outside the category;
  • generally accepts inborn errors of metabolism, such as phenylketonuria, as conditions a medical food could manage.

The guidance is non-binding, but it is FDA's stated current thinking.

Side by side

TopicEU FSMPUS medical food
StructureThree categories (complete standard, complete disease-adapted, incomplete), with composition rules in Delegated Regulation 2016/128No categories or composition standards in the Part 101 and 107 rules I read. Ingredients should be approved food or colour additives, GRAS, or prior-sanctioned substances (FAQ Q18)
Drug statusFood; disease prevention, treatment or cure claims banned (Art. 9(5) of 609/2013) [4]"Medical foods are not drugs" and are not subject to drug-specific requirements (FAQ Q3)
Nutrition labellingExpanded nutrition declaration mandatory whatever the pack size (Art. 6 of 2016/128)Exempt from Nutrition Facts under 21 CFR 101.9(j) [15]
Claims"Nutrition and health claims shall not be made" (Art. 7 of 2016/128)The nutrient content claim rules (§101.13(q)(4)(ii)) and health claim rules (§101.14(f)(2)) "do not apply to" medical foods [16][17][18][19]. A false or misleading claim still misbrands the product under FD&C Act 403(a)(1) (FAQ Q4-5)
Mandatory label contentRegulation 1169/2011 particulars plus Art. 5(2) of 2016/128: medical supervision statement, whether it can be the sole source of nutrition, "For the dietary management of …", product properties, precautions, and othersGeneral food labelling: statement of identity, net quantity, name and place of business, ingredient list, allergens, and the principal display panel and information panel rules (FAQ Q6, Q8)
Supervision wording"Must be used under medical supervision" is mandatoryNot required. FDA "would not object" to wording such as "must be used under the supervision of a physician". "Rx only" and National Drug Code (NDC) numbers on the label misbrand the product (FAQ Q16-17)
PrescriptionNot covered in the EU texts I readNot required: the prescription rule in FD&C Act 503(b) applies only to drugs (FAQ Q14)
Market entryLabel model sent to the competent authority of each Member State where sold, unless a national monitoring system exempts it (Art. 9 of 2016/128)I found no product notification. Facilities must register with FDA (FD&C Act 415), and FDA "does not maintain a comprehensive list" of medical foods (FAQ Q10-11)
Manufacturing and oversightGeneral EU food lawCGMP, low-acid canned and acidified food rules, emergency permit control (FAQ Q7), plus FDA's "Medical Foods Program - Import and Domestic" compliance program (FAQ Q12-13)

Infant products

In the EU, infant FSMPs are a subset of FSMP. They carry extra marketing limits under Article 8 of 2016/128: no infant pictures, advertising confined to baby-care and scientific publications, and no samples or retail promotion.

In the US, formulas for infants with "inborn errors of metabolism or low birth weight, or who otherwise have unusual medical or dietary problems" are a separate category, exempt infant formulas under 21 CFR 107.50 [20]. Unlike adult medical foods, they do go through FDA before sale:

  • For formulas sold at retail, the manufacturer "shall submit" the label, the full quantitative formulation and a description of the target medical conditions. The deadline was on or before 21 May 1986, or the 90th day before first processing, whichever is later [21].
  • Formulas not generally sold at retail must submit the same information [22].
  • Any reformulation that may reduce nutrient levels or availability must be filed before first processing [23].
  • FDA may impose extra conditions or withdraw exempt status [24].

The FAQ notes that medical foods "may also include" such formulas used for inborn errors of metabolism.

What this means for a product sold in both markets

  • An EU FSMP label will not work in the US as it stands. EU-required elements can be at odds with FDA's position, for example presenting the product as prescription-only. The US label must instead follow US formats (statement of identity, ingredient list, allergen declaration, English).
  • A US medical food may not qualify as an FSMP in the EU without reformulation and relabelling to meet 2016/128. That includes the mandatory nutrition declaration that the US exempts and dropping any claims.
  • The disease targets do not map neatly. FDA's guidance excludes diabetes, pregnancy and nutrient-deficiency diseases from US medical foods, so a product built around those cannot be marketed as a US medical food whatever its EU status. The EU texts I read set no parallel list of excluded conditions.
Q.04